Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction
| Autor: | James Yeager, Melissa Nelson, William Pfister, Mary Mahoney, Michael Rooney, Christopher P. Steidle |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Meatus Time Factors Urology Endocrinology Diabetes and Metabolism Administration Topical Vasodilator Agents Priapism Severity of Illness Index Drug Administration Schedule law.invention Electrocardiography Endocrinology Randomized controlled trial Double-Blind Method Erectile Dysfunction law Surveys and Questionnaires Severity of illness medicine Humans Alprostadil Adverse effect Dosage Forms business.industry Middle Aged medicine.disease Psychiatry and Mental health medicine.anatomical_structure Erectile dysfunction Treatment Outcome Reproductive Medicine Anesthesia Itching medicine.symptom business Penis |
| Zdroj: | The journal of sexual medicine. 6(2) |
| ISSN: | 1743-6109 |
| Popis: | Introduction Alprostadil is approved for treatment of male erectile dysfunction (ED) by injection or urethral insertion. Topical delivery of alprostadil offers an improved alternative. Aim To evaluate the long-term safety and efficacy of topical alprostadil cream. Methods This was a multicenter, open-label, long-term study in 1,161 patients (998 double-blind rollover; 163 naive) with ED. For the first 4 weeks, patients could administer eight doses of 200 mcg alprostadil to the penis meatus before intercourse (up to 2 per/week). Patients then self-selected to administer 300 or 100 mcg doses if hypo-responsive or hyper-responsive, respectively, or 200 mcg if no change, for up to 9 months (2 doses/week). Main Outcome Measures Safety evaluated patient/partner adverse events (AEs), changes in vital signs, clinical laboratory tests, physical examinations, and electrocardiograms. Efficacy assessed International Index of Erectile Function, Sexual Encounter Profile, Patient Self Assessment of Erection, and Global Assessment Questionnaire. Results Approximately 12% of patients discontinued due to hypo-/hyper-responsiveness, 16% withdrew consent for a variety of reasons, and less than 5% discontinued because of AEs. The majority of patients (73%) selected 300 mcg alprostadil as the final dose. The most common AEs involved application site burning or erythema (12.2%), meatal or glans pain (4.4%), and prolonged or painful erection (1.3%). Only 5 (0.4%) patients reported a prolonged erection of ≥4 hours (priapism). Vaginal burning or itching (2.1%) was reported most frequently by partners. The majority of patients (74%) demonstrated an overall improvement in erectile function on most end-points, especially after adjusting dose strength to their individual responsiveness. Conclusions Topical alprostadil cream was considered effective and safe by most patients and their partners, with most AEs limited to the application site. Dose adjustment to 300 mcg alprostadil facilitated the greatest improvement in erectile function in the majority of patients. A separate report will integrate patient data from the open-label extension and prior double-blind studies. Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, and Steidle C. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med 2009;6:520–534. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text